Meeder Asset Management’s Denali Therapeutics DNLI Stock Holding History

Meeder Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.65K	Buy	+142	New	+$2.92K	﹤0.01%	883
2025 Q4	–	Sell	-206	Closed	-$2.99K	–	926
2025 Q3	$2.99K	Buy	+206	New	+$2.96K	﹤0.01%	745
2025 Q1	–	Sell	-165	Closed	-$3.36K	–	937
2024 Q4	$3.36K	Buy	165 +6	+4%	+$154	﹤0.01%	872
2024 Q3	$4.63K	Buy	+159	New	+$3.94K	﹤0.01%	755
2021 Q4	–	Sell	-3,669	Closed	-$186K	–	1479
2021 Q3	$186K	Buy	3,669 +922	+34%	+$52K	0.01%	742
2021 Q2	$215K	Buy	2,747 +306	+13%	+$18.9K	0.01%	708
2021 Q1	$139K	Buy	+2,441	New	+$163K	0.01%	824
2020 Q4	–	Sell	-2,426	Closed	-$88K	–	1964
2020 Q3	$88K	Buy	2,426 +1,960	+421%	+$59K	0.01%	821
2020 Q2	$13K	Sell	466 -1,047	-69%	-$24.6K	﹤0.01%	1239
2020 Q1	$26K	Buy	+1,513	New	+$31.6K	﹤0.01%	1135
2019 Q1	–	Sell	-318	Closed	-$7K	–	1733
2018 Q4	$7K	Sell	318 -79	-20%	-$1.43K	﹤0.01%	1329
2018 Q3	$9K	Buy	+397	New	+$6.57K	﹤0.01%	1183

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meeder Asset Management's DNLI Position: Q2 2026 in Review

Meeder Asset Management opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 142 shares worth $3.65K. The stake represents ﹤0.01% of the portfolio and ranks #883 among its holdings. This is a return to the name: Meeder Asset Management previously reported a position in DNLI as recently as Q3 2025.

Meeder Asset Management first reported a position in DNLI in Q3 2018 and has held it in 12 quarters since. The position peaked at $215K in Q2 2021. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Meeder Asset Management held 142 shares of Denali Therapeutics worth $3.65K as of Q2 2026.
Denali Therapeutics was a new Meeder Asset Management position in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #883 holding.
Meeder Asset Management first reported a position in Denali Therapeutics in Q3 2018 and has held it in 12 quarters since.
Meeder Asset Management's Denali Therapeutics position peaked at $215K in Q2 2021.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.